A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Inclusion Criteria: * Have type 2 diabetes * Have an HbA1c ≥7.5% to ≤10.5% at screening * Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening * Diet and exercise * Stable dose of metformin * Sodium-glucose cotransporter-2 (SGLT2) inhibitor * Have had a stable body weight (\1 year prior to screening * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include * basal or squamous cell skin cancer * in situ carcinomas of the cervix, or * in situ prostate cancer * Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months: * amylin RA * dual amylin and calcitonin RA * glucagon-like peptide-1 receptor (GLP-1) RA * glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA * GLP-1/glucagon (GCG) RAs, or * GIP/GLP-1/GCG RAs * Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides * Have used insulin for diabetic control within the prior year (short term use in certain situations allowed